Align Technology (ALGN) Stifel Jaws & Paws Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel Jaws & Paws Conference 2026 summary
2 Jun, 2026Key innovation and product initiatives
Transitioning from standalone products to integrated solutions, such as enhanced palatal expanders and mandibular advancement devices addressing skeletal issues.
Direct fabrication technology is being piloted, aiming to simplify multi-issue treatments and improve scalability, with broader rollout expected as pilots transition to general release.
Financing initiatives and partnerships with external providers are being expanded to improve patient affordability and conversion rates, with momentum expected to build into next year.
Ortho-restorative initiatives involving labs are in pilot stages, with gradual rollout planned as adoption grows.
Direct fabrication products are currently dilutive to gross margins but expected to be neutral by next year and accretive by 2028 as scale increases.
Financial performance and guidance
Q2 2026 guidance reflects prudent assumptions, with revenue expected to rise about 1% at the midpoint, below the typical 3-4% sequential increase, due to geopolitical and macroeconomic uncertainties.
Margin expansion of 100 basis points is anticipated this year, driven by restructuring, product mix improvements, and ongoing productivity initiatives.
R&D as a percentage of revenue is expected to normalize as new products move from development to commercialization and revenue grows.
ASPs are expected to be flat to down 1% for 2026, aided by FX and VAT benefits, with mix effects from growth in lower ASP markets and products.
Regional and market dynamics
North America faces challenges in retail, but DSOs are achieving double-digit growth through active conversion strategies and financing options.
International markets (APAC, EMEA, LATAM) are experiencing broad-based double-digit growth, especially in under-penetrated countries like Turkey, India, and Southeast Asia.
DSOs account for about 35% of North American volume and 25% globally, providing a positive mix shift and operational leverage.
Latest events from Align Technology
- International growth, product innovation, and digital adoption drive double-digit gains and margin expansion.ALGN
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - International growth, product innovation, and integration drive conversion and margin gains.ALGN
Jefferies Global Healthcare Conference 20264 Jun 2026 - AI-powered digital workflows and 3D printing are transforming orthodontic care and patient engagement.ALGN
46th Annual William Blair Growth Stock Conference3 Jun 2026 - Q1 2026 revenue up 6.2% to $1.04B, with record aligner volumes and $113M net income.ALGN
Q1 20266 May 2026 - Voting standard for Proposal 4 clarified; majority approval of shares present or represented required.ALGN
Proxy filing17 Apr 2026 - Record Q4 and FY2025 revenues, strong Clear Aligner and DSO growth, and positive 2026 outlook.ALGN
Q4 202517 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing7 Apr 2026 - Virtual Annual Meeting to address director elections, compensation, auditor, and bylaw proposals.ALGN
Proxy filing7 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing27 Mar 2026